ICU Medical (NASDAQ:ICUI) Hits New 1-Year High at $181.16

ICU Medical, Inc. (NASDAQ:ICUI)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $181.16 and last traded at $181.16, with a volume of 12675 shares changing hands. The stock had previously closed at $179.00.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ICUI shares. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th. KeyCorp increased their target price on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Raymond James raised their price objective on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $149.00.

ICU Medical Price Performance

The company has a 50 day moving average of $144.47 and a 200-day moving average of $119.07. The stock has a market capitalization of $4.41 billion, a P/E ratio of -73.42 and a beta of 0.65. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The firm had revenue of $596.50 million for the quarter, compared to analysts’ expectations of $556.64 million. During the same period last year, the business posted $1.58 earnings per share. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Sell-side analysts predict that ICU Medical, Inc. will post 3.76 EPS for the current year.

Insiders Place Their Bets

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the sale, the vice president now directly owns 4,482 shares of the company’s stock, valued at $645,901.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the sale, the vice president now directly owns 4,482 shares of the company’s stock, valued at $645,901.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,320,691.72. The disclosure for this sale can be found here. Insiders have sold 28,552 shares of company stock valued at $4,537,802 over the last three months. Company insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Truist Financial Corp acquired a new position in shares of ICU Medical during the second quarter valued at $310,000. Creative Planning increased its holdings in shares of ICU Medical by 75.5% during the second quarter. Creative Planning now owns 3,906 shares of the medical instruments supplier’s stock valued at $464,000 after purchasing an additional 1,680 shares during the period. Lighthouse Investment Partners LLC increased its holdings in shares of ICU Medical by 484.4% during the second quarter. Lighthouse Investment Partners LLC now owns 62,826 shares of the medical instruments supplier’s stock valued at $7,461,000 after purchasing an additional 52,076 shares during the period. Millennium Management LLC increased its holdings in shares of ICU Medical by 327.8% during the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock valued at $16,158,000 after purchasing an additional 104,264 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in ICU Medical during the second quarter worth about $70,000. 96.10% of the stock is owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.